Mersana Therapeutics Inc (NASDAQ:MRSN) Expected to Post Earnings of -$0.37 Per Share

Wall Street analysts predict that Mersana Therapeutics Inc (NASDAQ:MRSN) will post earnings of ($0.37) per share for the current fiscal quarter, Zacks reports. Three analysts have provided estimates for Mersana Therapeutics’ earnings. The lowest EPS estimate is ($0.39) and the highest is ($0.35). Mersana Therapeutics posted earnings of ($0.75) per share during the same quarter last year, which suggests a positive year over year growth rate of 50.7%. The business is expected to report its next quarterly earnings results on Tuesday, November 12th.

According to Zacks, analysts expect that Mersana Therapeutics will report full year earnings of ($0.64) per share for the current financial year, with EPS estimates ranging from ($0.86) to ($0.38). For the next fiscal year, analysts anticipate that the company will report earnings of ($1.44) per share, with EPS estimates ranging from ($1.84) to ($1.20). Zacks’ EPS calculations are an average based on a survey of sell-side analysts that that provide coverage for Mersana Therapeutics.

Mersana Therapeutics (NASDAQ:MRSN) last issued its earnings results on Thursday, August 8th. The company reported ($0.36) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.38) by $0.02. The business had revenue of $0.20 million during the quarter, compared to the consensus estimate of $1.08 million. Mersana Therapeutics had a negative return on equity of 63.92% and a negative net margin of 77.78%.

A number of brokerages recently issued reports on MRSN. Cowen reissued a “buy” rating on shares of Mersana Therapeutics in a research report on Sunday, June 2nd. ValuEngine raised Mersana Therapeutics from a “hold” rating to a “buy” rating in a research report on Thursday, August 1st. Finally, Zacks Investment Research cut Mersana Therapeutics from a “buy” rating to a “hold” rating in a report on Saturday. One equities research analyst has rated the stock with a sell rating, one has assigned a hold rating and six have issued a buy rating to the stock. The stock presently has a consensus rating of “Buy” and an average target price of $11.63.

Shares of NASDAQ:MRSN traded down $0.02 during midday trading on Friday, reaching $2.82. 552 shares of the company’s stock were exchanged, compared to its average volume of 151,308. The stock has a 50 day moving average price of $3.80. The company has a current ratio of 6.24, a quick ratio of 6.24 and a debt-to-equity ratio of 0.02. The company has a market capitalization of $148.69 million, a PE ratio of -1.00 and a beta of 1.37. Mersana Therapeutics has a fifty-two week low of $2.79 and a fifty-two week high of $15.93.

A number of hedge funds have recently bought and sold shares of MRSN. Northern Trust Corp grew its stake in shares of Mersana Therapeutics by 13.4% in the second quarter. Northern Trust Corp now owns 204,194 shares of the company’s stock valued at $827,000 after buying an additional 24,126 shares in the last quarter. Public Employees Retirement System of Ohio bought a new stake in shares of Mersana Therapeutics during the 2nd quarter worth $94,000. Renaissance Technologies LLC boosted its stake in shares of Mersana Therapeutics by 52.4% during the 2nd quarter. Renaissance Technologies LLC now owns 266,020 shares of the company’s stock worth $1,077,000 after acquiring an additional 91,500 shares in the last quarter. Bank of New York Mellon Corp boosted its stake in shares of Mersana Therapeutics by 176.7% during the 2nd quarter. Bank of New York Mellon Corp now owns 107,201 shares of the company’s stock worth $434,000 after acquiring an additional 68,457 shares in the last quarter. Finally, Charles Schwab Investment Management Inc. boosted its stake in shares of Mersana Therapeutics by 144.0% during the 2nd quarter. Charles Schwab Investment Management Inc. now owns 85,045 shares of the company’s stock worth $345,000 after acquiring an additional 50,195 shares in the last quarter. Hedge funds and other institutional investors own 77.40% of the company’s stock.

About Mersana Therapeutics

Mersana Therapeutics, Inc, a clinical stage biopharmaceutical company focusing on the development of antibody drug conjugate (ADC) for cancer patients with unmet need. The company develops Dolaflexin, a platform, which is used to generate a pipeline of proprietary ADC product candidates to address patient populations that are not amenable to treat with traditional ADC-based therapies.

Featured Story: What is Put Option Volume?

Get a free copy of the Zacks research report on Mersana Therapeutics (MRSN)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Earnings History and Estimates for Mersana Therapeutics (NASDAQ:MRSN)

Receive News & Ratings for Mersana Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Mersana Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.